循环可溶性程序性死亡-1水平可能将免疫耐受期与其他阶段和

StephenW

Oncotarget. 2017 May 2. doi: 10.18632/oncotarget.17546. [Epub ahead of print]
Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection.
Li N1, Zhou Z1, Li F1, Sang J1, Han Q1, Lv Y2,3, Zhao W1, Li C1, Liu Z1,3.
Author information

1    Department of Infectious Diseases, First Affiliated Hospital of Xi'an Jiaotong University, Xi' an 710061, Shaanxi, China.
2    Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi, China.
3    Institute of Advanced Surgical Technology and Engineering, Xi'an Jiaotong University, Xi' an 710061, Shaanxi, China.

Abstract

Programmed death-1 (PD-1) is involved in the immune dysfunction of hepatitis B virus (HBV) infection and hepatocellular carcinoma (HCC). This study analyzed the association of circulating soluble PD-1 (sPD-1) levels with the phases and clinical diseases in chronic HBV infection. Serum sPD-1 levels were determined by enzyme linked immunosorbent assay in patients with different phases and liver diseases of chronic HBV infection. The sPD-1 levels in patients with chronic HBV infection were significantly elevated compared with HBV infection resolvers or healthy controls. According to phases, sPD-1 level in immune-tolerant phase (IT) was significantly lower than in other phases. Multivariate analysis showed that sPD-1 was an independent factor associated with IT. Area under the receiver operating characteristic (ROC) curves (AUC) showed that sPD-1 was significantly discriminative of IT from other phases with a cut-off of 1.535 ng/mL (AUC, 0.984; P<0.001). According to clinical diseases, sPD-1 level in HBV-related HCC was significantly higher than in other clinical diseases. Multivariate analysis showed that sPD-1 was an independent factor associated with HCC. The sPD-1 was significantly discriminative of HCC from other clinical diseases with a cut-off of 6.058 ng/mL (AUC, 0.962; P<0.001). The sPD-1 levels were significantly associated with HCC patients' overall survival. HCC resection resulted in remarkable reduction in sPD-1 levels. These results demonstrate the involvement of sPD-1 in the disease course of chronic HBV infection and indicate the potential to apply sPD-1 as a biomarker for differentiating IT from other phases and HCC from other disease conditions in chronic HBV infection.
KEYWORDS:

clinical diseases; hepatitis B virus; hepatocellular carcinoma; infection phases; soluble PD-1

PMID:
    28545019
DOI:
    10.18632/oncotarget.17546

StephenW

Oncotarget。 2017年5月2. doi：10.18632 / oncotarget.17546。 [提前印刷]
循环可溶性程序性死亡-1水平可能将免疫耐受期与其他阶段和肝细胞癌与慢性乙型肝炎病毒感染中的其他临床疾病区分开来。
李N1，周Z1，李F1，桑杰1，韩Q1，Lv Y2,3，赵W1，李C1，刘Z1 3。
作者信息

1西安交通大学第一附属医院传染病科，陕西西安710061。
2西安交通大学第一附属医院肝胆外科，陕西西安710061。
3西安交通大学先进手术技术与工程研究所，陕西西安710061。

抽象

程序性死亡-1（PD-1）涉及乙型肝炎病毒（HBV）感染和肝细胞癌（HCC）的免疫功能障碍。本研究分析了循环可溶性PD-1（sPD-1）水平与慢性HBV感染期和临床疾病的关系。血清sPD-1水平通过酶联免疫吸附测定法测定慢性HBV感染患者不同期和肝病。慢性HBV感染患者的sPD-1水平与HBV感染症候群或健康对照相比显着升高。根据阶段，免疫耐受期（IT）中的sPD-1水平显着低于其他阶段。多变量分析表明，sPD-1是与IT相关的独立因素。受试者工作特征（ROC）曲线（AUC）下的面积显示，sPD-1与其他相显着区别于IT，其间隔为1.535ng / mL（AUC，0.984; P <0.001）。根据临床疾病，HBV相关HCC的sPD-1水平明显高于其他临床疾病。多变量分析显示sPD-1是与HCC相关的独立因素。 sPD-1与其他临床疾病的HCC有显着差异，截止值为6.058 ng / mL（AUC，0.962; P <0.001）。 sPD-1水平与HCC患者的总体生存率显着相关。 HCC切除导致sPD-1水平显着降低。这些结果表明sPD-1参与慢性HBV感染的疾病过程，并表明将sPD-1应用于将IT与其他阶段和HCC与慢性HBV感染中其他疾病状况区分开来的生物标志物的潜力。
关键词：

临床疾病;乙型肝炎病毒;肝细胞癌;感染阶段可溶性PD-1

结论：
    28545019
DOI：
    10.18632 / oncotarget.17546

StephenW

http://www.impactjournals.com/on ... mp;path%5B%5D=56140